D

DiCE Molecules

37 employees

Dice Therapeutics is a clinical-stage biopharmaceutical company that makes medicines for chronic autoimmune and inflammatory diseases.

Basic info

Industry

biotechnology

Sectors

Biotechnology
Medical Device
Medical

Date founded

2013

Funding rounds raised

Total raised

$80M

from 21 investors over 21 rounds

D

DiCE Molecules raised $60M on August 24, 2021

Investors: Eventide Asset Management, New Leaf Venture Partners, Soleus Capital Management, L.P., Northpond Ventures, Logos Global Management, LP, Sands Capital Management, Driehaus Capital Management LLC, Osage University Partners (OUP) and RA Capital Management, L.P.

D

DiCE Molecules raised $80M on January 8, 2021

Investors: Sanofi Ventures, Soleus Capital Management, L.P., Osage University Partners (OUP), Northpond Ventures, RA Capital Management, L.P., New Leaf Venture Partners, Driehaus Capital Management LLC, Eventide Asset Management, Sands Capital Management and Asymmetry Capital Management, L.P.

D

DiCE Molecules raised $41M on July 11, 2018

Investors: Northpond Ventures

D

DiCE Molecules raised undisclosed on January 1, 2014

Investors: Miller Investment Management, LP

FAQ